Francesca Panin

Francesca Panin

Auto-generated profile, based on publicly available information

Francesca Panin

Dipartimento di Scienze del Farmaco, Università di Sassari, Via Muroni 23/A, 07100 Sassari, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Phytomedicine
Verified
Journal Article
Closed access
APAlessandra Tiziana Peana
Alessandra Tiziana Peana
Paolo D'aquilaPaolo D'aquila
Paolo D'aquila
FPF. Panin
F. Panin
GSG. Serra
G. Serra
PPP. Pippia
P. Pippia
MMM.D.L. Moretti
M.D.L. Moretti

3 January 2014 in Science
Verified
Journal Article
Closed access
PDF file
Monique ValléeMonique Vallée
Monique Vallée
SVSergio Vitiello
Sergio Vitiello
LBLuigi Bellocchio
Luigi Bellocchio
EHEtienne Hébert-Chatelain
Etienne Hébert-Chatelain
SMStéphanie Monlezun
Stéphanie Monlezun
PPPier Vincenzo Piazza
Pier Vincenzo Piazza
Counteracting Cannabis: What is the role of steroid hormones in vulnerability to addiction? Working with rodents, Vallée et al. (p. 94 ) found that all major drugs of abuse (morphine, cocaine, alcohol, nicotine) increase neurosteroid levels, with the active ingredient in cannabis (THC) inducing a particularly large increase. THC and other drugs increased levels of pregnenolone, long thought to be an inactive precursor of downstream active steroids. Pregnenolone antagonized most of the known behavioral and somatic effects of THC.

21 August 2015 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
Alpar S. LazarAlpar S. Lazar
Alpar S. Lazar
FPFrancesca Panin
Francesca Panin
AGAnna O. G. Goodman
Anna O. G. Goodman
SLStanley E. Lazic
Stanley E. Lazic
ZLZSOLT LÁZÁR
ZSOLT LÁZÁR
RBRoger A. Barker
Roger A. Barker
Objective: Huntington disease (HD) is a fatal autosomal dominant, neurodegenerative condition characterized by progressively worsening motor and nonmotor problems including cognitive and neuropsychiatric disturbances, along with sleep abnormalities and weight loss. However, it is not known whether sleep disturbances and metabolic abnormalities underlying the weight loss are present at a premanifest stage.Methods: We performed a comprehensive sleep and metabolic study in 38 premanifest gene carrier individuals and 36 age‐ and sex‐matched controls. The study consisted of 2 weeks of actigraphy at home, 2 nights of polysomnography and multiple sleep latency tests in the laboratory, and body composition assessment using dual energy x‐ray absorptiometry scanning with energy expenditure measured over 10 days at home by doubly labeled water and for 36 hours in the laboratory by indirect calorimetry along with detailed cognitive and clinical assessments. We performed a principal component analyses across all measures within each studied domain.Results: Compared to controls, premanifest gene carriers had more disrupted sleep, which was best characterized by a fragmented sleep profile. These abnormalities, as well as a theta power (4–7Hz) decrease in rapid eye movement sleep, were associated with disease burden score. Objectively measured sleep problems coincided with the development of cognitive, affective, and subtle motor deficits and were not associated with any metabolic alterations.Interpretation: The results show that among the earliest abnormalities in premanifest HD is sleep disturbances. This raises questions as to where the pathology in HD begins and also whether it could drive some of the early features and even possibly the pathology. Ann Neurol 2015;78:630–648

1 May 2004 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Paolo D'aquilaPaolo D'aquila
Paolo D'aquila
FPFrancesca Panin
Francesca Panin
GSGino Serra
Gino Serra

7 December 2002 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Paolo D'aquilaPaolo D'aquila
Paolo D'aquila
APAlessandra Tiziana Peana
Alessandra Tiziana Peana
FPFrancesca Panin
Francesca Panin
CGChiara Grixoni
Chiara Grixoni
MCMaria Cossu
Maria Cossu
GSGino Serra
Gino Serra

1 March 2012 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
FPFrancesca Panin
Francesca Panin
ACAdeline Cathala
Adeline Cathala
PPPier Vincenzo Piazza
Pier Vincenzo Piazza
USUmberto Spampinato
Umberto Spampinato